Deerfield Management Company, L.P. (Series C) Savara Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Savara Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 6,465,777 shares of SVRA stock, worth $19.3 Million. This represents 0.51% of its overall portfolio holdings.
Number of Shares
6,465,777Holding current value
$19.3 Million% of portfolio
0.51%Shares
3 transactions
Others Institutions Holding SVRA
# of Institutions
128Shares Held
158MCall Options Held
67.6KPut Options Held
29.4K-
Nea Management Company, LLC Timonium, MD24.5MShares$72.9 Million7.93% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$43.4 Million11.08% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$36.8 Million6.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.62MShares$25.7 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$24.3 Million1.86% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $340M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.